ifosfamide has been researched along with cyclosporine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Brugarolas, A; Cid, J; González-Manzano, R; Piasecki, CC | 1 |
| Jelkmann, W; Wolff, M | 1 |
| Chan, HS; Doyle, J; Greenberg, ML; Karaskov, V; Koren, G; Malkin, D; Moncica, I; Theis, JG | 2 |
| Beulz-Riché, D; Ratanasavanh, D; Riché, C; Robert, J | 1 |
| Aleksa, K; Chen, N; Koren, G | 1 |
| Chiba, S; Izutsu, K; Kako, S; Kanda, Y; Kurokawa, M; Motokura, T; Oshima, K; Sato, H | 1 |
1 review(s) available for ifosfamide and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for ifosfamide and cyclosporine
| Article | Year |
|---|---|
Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Cyclosporine; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Immunity, Cellular; Lymphocyte Count; Lymphocyte Subsets; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Remission Induction | 1995 |
Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Cyclophosphamide; Cyclosporine; Dactinomycin; Drug Interactions; Etoposide; Fever; Humans; Ifosfamide; Immunosuppressive Agents; Neutropenia; Patient Admission; Retrospective Studies; Sarcoma; Sepsis; Soft Tissue Neoplasms; Vincristine | 1998 |
14 other study(ies) available for ifosfamide and cyclosporine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures.
Topics: Animals; Antineoplastic Agents; Azathioprine; Colchicine; Cyclophosphamide; Cyclosporine; Cytarabine; Daunorubicin; Erythropoietin; Humans; Ifosfamide; Immunosuppressive Agents; L-Lactate Dehydrogenase; Liver Neoplasms, Experimental; Methotrexate; Organoplatinum Compounds; Tetrazolium Salts; Tumor Cells, Cultured; Vincristine | 1993 |
Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Transfusion; Chi-Square Distribution; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Dactinomycin; Etoposide; Female; Fever; Humans; Ifosfamide; Male; Neutropenia; Pilot Projects; Platelet Transfusion; Retrospective Studies; Sarcoma; Sepsis; Treatment Outcome; Vincristine | 2000 |
Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes.
Topics: Antibiotics, Antineoplastic; Cyclophosphamide; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Doxorubicin; Drug Interactions; Humans; Ifosfamide; Microsomes, Liver; Mixed Function Oxygenases; Paclitaxel; Tamoxifen | 2002 |
Drug-induced nephrotoxicity in children: pharmacologically based prevention of long-term impairment.
Topics: Amphotericin B; Child; Cyclosporine; Humans; Ifosfamide; Kidney Diseases; Kidney Function Tests; Time Factors | 2007 |
Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cryptogenic Organizing Pneumonia; Cyclophosphamide; Cyclosporine; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Lymphoma, T-Cell, Peripheral; Methotrexate; Neoplasm Recurrence, Local; Palatal Neoplasms; Remission Induction; Salvage Therapy; Transplantation, Homologous; Vincristine | 2007 |